In a single-arm phase 2 study of the AspaMetDex regimen (L-asparaginase/methotrexate/dexamethasone) in patients with R/R extranodal NKTCL and no prior asparaginase therapy, the ORR after three cycles of treatment was 77.8% (N = 18) [26]. Here, ASPG is linked to extranodal nasal NK/T cell lymphoma.